PROCAPS develops, manufactures and sells prescription drugs and over-the-counter products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements, such as omega 3 fish oils and high-potency clinical compounds. It has a portfolio of over 1,300 finished formulations, representing more than 2,100 SKUs in 12 different pharmaceutical forms1. About 42 percent of all PROCAPS products are softgel capsules.
PROCAPS’ products are developed to improve the consumer experience. Since the outer shell is pliable, softgels are easier to swallow than tablets, and this is especially helpful to older consumers who often struggle taking tablets. As a result, many of PROCAP’s prescription medications are treatments serving aging people. Its products treat widespread chronic and life-threatening diseases. PROCAPS medications cover nine therapeutic areas and address about 67 different disease profiles including cardiology, dermatology, gastroenterology, endocrinology, neurology, oncology, ophthalmology, respiratory and women’s health.
In 2009, PROCAPS became the first Latin American pharmaceutical company to have a drug approved by the U.S. Food and Drug Administration (FDA). The high-quality endorsement opened the door for its products to be exported to the US market and led to contracts with major pharmaceutical companies.
PROCAPS skills in research and development positioned it to secure the U.S. patent for incorporating Non-Steroidal Anti-Inflammatory Drugs (NSAID) into softgels, and it is the exclusive manufacturer of Pfizer’s Advil (Ibuprofen) Liqui-Gel product line for the Latin American market. It holds 25 patents and has filed 52 patent applications around the world, giving PROCAPS a global reputation as an innovator to deliver on its quality of service promise, PROCAPS relies on over 5,000 employees across 15 countries to develop, manufacture and distribute its products. It employs high-skilled personnel. Its in-house research and development department has more than 70 scientists and technicians, of which more than 25 percent have master’s degrees and PhDs. Fifty percent of its staff are women, including the Vice President for Corporate Affairs and the Vice President of Compliance.
PROCAPS has created a participative culture aimed at discovering new markets, identifying unspoken needs, and generating new products that leverage its specialized technologies. Today, PROCAPS brings innovation, differentiation and value to patients and doctors in more sophisticated ways by offering proprietary technology that includes eight advanced delivery systems.